方盛製藥(603998.SH):子公司中藥創新藥研發項目獲得藥物臨牀試驗批準通知書
格隆匯7月11日丨方盛製藥(603998.SH)公佈,公司全資子公司雲南方盛融和藥業有限公司(以下簡稱“方盛融和”)與雲南中醫藥大學共同研發的中藥創新藥研發項目香芩解熱顆粒收到國家藥品監督管理局覈準簽發的《藥物臨牀試驗批準通知書》。香芩解熱顆粒項目爲公司與雲南中醫藥大學共同研發。
香芩解熱顆粒的處方爲臨牀經驗方,是岐黃學者、中華中醫藥學會兒科分會主任委員、雲南省中醫藥領軍人才、雲南省名中醫熊磊教授經驗方,經長期臨牀應用療效肯定,用於溼熱鬱表型流行性感冒,症見發熱惡寒、咽痛、頭痛、身痛、睏倦乏力、鼻塞、流涕、咳嗽、納呆、大便黏滯不爽、舌質紅苔黃膩等症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.